Recombinant Human VEGF-C (Cys156Ser) Protein

Carrier Free

Catalog # Availability Size / Price Qty
752-VC-025/CF

With Carrier

Catalog # Availability Size / Price Qty
752-VC-025
Product Details
Citations (16)
FAQs
Reviews

Recombinant Human VEGF-C (Cys156Ser) Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96:9671. The ED50 for this effect is 1-5 µg/mL. Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGF R3/Flt‑4 Fc Chimera (Catalog # 349-F4) at 5 µg/mL (100 µL/well) can bind  Recombinant Human VEGF‑C (Cys156Ser) with an apparent Kd <40 nM.
Source
Mouse myeloma cell line, NS0-derived human VEGF-C protein
Thr103-Arg227 (Cys156Ser), with a C-terminal 10-His tag
Accession #
N-terminal Sequence
Analysis
Thr103
Predicted Molecular Mass
15.4 kDa
SDS-PAGE
22-24 kDa, reducing conditions

Product Datasheets

752-VC (with carrier)

752-VC/CF (carrier free)

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

752-VC

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

752-VC/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGF-C

Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors (1). VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4 (2-4). Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1 (2, 4). Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis (5-8). VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes (9-12). It also induces physiological and intratumoral neoangiogenesis and vessel sprouting through interactions with VEGF R2 (8, 13, 14).

References
  1. Chen, J.-C. et al. (2013) Int. J. Mol. Sci. 14:88.
  2. Joukov, V. et al. (1996) EMBO J. 15:290.
  3. Kukk, E. et al. (1996) Development 122:3829.
  4. Joukov, V. et al. (1997) EMBO J. 16:3898.
  5. Karkkainen, M. et al. (2004) Nat. Immunol. 5:74.
  6. Jeltsch, M. et al. (1997) Science 276:1423.
  7. Makinen, T. et al. (2001) Nat. Med. 7:199.
  8. Laakkonen, P. et al. (2007) Cancer Res. 67:593.
  9. Hoshida, T. et al. (2006) Cancer Res. 66:8065.
  10. Mandriota, S.J. et al. (2001) EMBO J. 20:672.
  11. Skobe, M. et al. (2001) Nat. Med. 7:192.
  12. Padera, T.P. et al. (2002) Science 296:1883.
  13. Tammela, T. et al. (2008) Nature 454:656.
  14. Cao, Y. et al. (1998) Proc. Natl. Acad. Sci. 95:14389.
Long Name
Vascular Endothelial Growth Factor C
Entrez Gene IDs
7424 (Human); 22341 (Mouse)
Alternate Names
Flt4 ligand; Flt4-L; vascular endothelial growth factor C; Vascular endothelial growth factor-related protein; VEGFC; VEGF-C; VRPFLT4 ligand DHM

Citations for Recombinant Human VEGF-C (Cys156Ser) Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

16 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Induced dural lymphangiogenesis facilities soluble amyloid-beta clearance from brain in a transgenic mouse model of Alzheimer's disease
    Authors: YR Wen, JH Yang, X Wang, ZB Yao
    Neural Regen Res, 2018;13(4):709-716.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction
    Authors: JM Vieira, S Norman, C Villa Del, TJ Cahill, DN Barnette, M Gunadasa-R, LA Johnson, DR Greaves, CA Carr, DG Jackson, PR Riley
    J. Clin. Invest., 2018;0(0):.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  3. Impact of Lymphangiogenesis on Cardiac Remodeling After Ischemia and Reperfusion Injury
    Authors: Y Shimizu, R Polavarapu, KL Eskla, Y Pantner, CK Nicholson, M Ishii, D Brunnhoelz, R Mauria, A Husain, N Naqvi, T Murohara, JW Calvert
    J Am Heart Assoc, 2018;7(19):e009565.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Biology of Vascular Endothelial Growth Factor C in the Morphogenesis of Lymphatic Vessels
    Authors: K Rauniyar, SK Jha, M Jeltsch
    Front Bioeng Biotechnol, 2018;6(0):7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  5. Structural and functional features of central nervous system lymphatic vessels.
    Authors: Louveau A, Smirnov I, Keyes T, Eccles J, Rouhani S, Peske J, Derecki N, Castle D, Mandell J, Lee K, Harris T, Kipnis J
    Nature, 2015;523(7560):337-41.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  6. Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis.
    Authors: Heishi T, Hosaka T, Suzuki Y, Miyashita H, Oike Y, Takahashi T, Nakamura T, Arioka S, Mitsuda Y, Takakura T, Hojo K, Matsumoto M, Yamauchi C, Ohta H, Sonoda H, Sato Y
    Am. J. Pathol., 2010;176(4):1950-8.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  7. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis.
    Authors: Kajiya K, Sawane M, Huggenberger R, Detmar M
    J. Invest. Dermatol., 2009;129(5):1292-8.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  8. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway.
    Authors: Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML
    Carcinogenesis, 2009;30(12):2005-13.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. The resolution of lymphedema by interstitial flow in the mouse tail skin.
    Authors: Uzarski J, Drelles MB, Gibbs SE, Ongstad EL, Goral JC, McKeown KK, Raehl AM, Roberts MA, Pytowski B, Smith MR, Goldman J
    Am. J. Physiol. Heart Circ. Physiol., 2008;294(3):H1326-34.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  10. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.
    Authors: Shin JW, Huggenberger R, Detmar M
    Blood, 2008;112(6):2318-26.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1.
    Authors: Kilic N, Oliveira-Ferrer L, Neshat-Vahid S, Irmak S, Obst-Pernberg K, Wurmbach JH, Loges S, Kilic E, Weil J, Lauke H, Tilki D, Singer BB, Ergun S
    Blood, 2007;110(13):4223-33.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  12. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
    Authors: Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, Huss R, Graeb C, Jauch KW, Heeschen C, Guba M
    Kidney Int., 2007;71(8):771-7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain.
    Authors: Le Bras B, Barallobre MJ, Homman-Ludiye J, Ny A, Wyns S, Tammela T, Haiko P, Karkkainen MJ, Yuan L, Muriel MP, Chatzopoulou E, Breant C, Zalc B, Carmeliet P, Alitalo K, Eichmann A, Thomas JL
    Nat. Neurosci., 2006;9(3):340-8.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Regulation of lymphatic capillary regeneration by interstitial flow in skin.
    Authors: Goldman J, Conley KA, Raehl A, Bondy DM, Pytowski B, Swartz MA, Rutkowski JM, Jaroch DB, Ongstad EL
    Am. J. Physiol. Heart Circ. Physiol., 2006;292(5):H2176-83.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  15. Loss of Tie2 receptor compromises embryonic stem cell-derived endothelial but not hematopoietic cell survival.
    Authors: Hamaguchi I, Morisada T, Azuma M, Murakami K, Kuramitsu M, Mizukami T, Ohbo K, Yamaguchi K, Oike Y, Dumont DJ, Suda T
    Blood, 2005;107(3):1207-13.
    Species: Mouse
    Sample Types: Whole Cells
  16. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis.
    Authors: Shin JW, Min M, Larrieu-Lahargue F, Canron X, Kunstfeld R, Nguyen L, Henderson JE, Bikfalvi A, Detmar M, Hong YK
    Mol. Biol. Cell, 2005;17(2):576-84.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human VEGF-C (Cys156Ser) Protein

There are currently no reviews for this product. Be the first to review Recombinant Human VEGF-C (Cys156Ser) Protein and earn rewards!

Have you used Recombinant Human VEGF-C (Cys156Ser) Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review